譽衡生物實施股權激勵引入有限合夥持股平台 譽衡藥業(002437.SZ)放棄增資優先認繳權
格隆匯11月12日丨譽衡藥業(002437.SZ)公佈,公司參股公司廣州譽衡生物科技有限公司(簡稱“譽衡生物”)為充分調動其管理團隊及核心人員等工作積極性,保障團隊穩定、積極、長期投入工作,擬實施股權激勵計劃,激勵對象擬通過先行搭建合夥企業持股平台的方式對譽衡生物進行增資,綜合考慮譽衡生物未來發展,公司及譽衡生物其他股東共同放棄該次增資優先認繳權。
持股平台上海昱盛博然企業管理合夥企業(有限合夥)、上海睿亞譽生企業管理合夥企業(有限合夥)對譽衡生物增資完成後,將分別持有譽衡生物8%、18%股權,合計持有26%股權;持股平台的增資定價原則將按照公司註冊資本最低價格要求每註冊資本1元定價,未來激勵對象將以其自有資金,按每註冊資本對應1元人民幣進行貨幣出資。
截止目前,譽衡生物PD-1產品賽帕利單抗注射液首個申請適應症為復發或難治性經典霍奇金淋巴瘤,已上市銷售,同時,譽衡生物正在加快推進賽帕利單抗注射液在宮頸癌適應症領域的臨牀工作,在目前企業發展的重要時點,管理團隊及核心員工等對譽衡生物的未來發展至關重要,譽衡生物通過實施股權激勵方式,將激勵對象個人利益與譽衡生物發展結合,激發管理團隊等積極性,有利於避免核心員工流失等問題並吸引更多優秀人才,促進譽衡生物的可持續發展。
目前,公司持有譽衡生物49%股權,該次持股平台增資完成後,公司對譽衡生物的持股比例將降至36.26%,譽衡生物仍為公司的參股公司,公司放棄譽衡生物該次增資認繳權主要是綜合考慮譽衡生物長遠發展而做出的決策,不會對公司的主營業務和持續經營能力造成重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.